Photo of Tanja Pejovic, M.D., Ph.D.

Tanja Pejovic M.D., Ph.D.

Dr. Pejovic has advanced training in treating all cancers of the female reproductive organs (gynecologic cancers). Her research interest in how ovarian cancer develops in the body's cells has given her a deep understanding of this disease. While she continues to work with other OHSU doctors and scientists on applying the latest scientific discoveries to patient care, Dr. Pejovic is also interested in holistic approaches to cancer care and is pursuing formal training in cancer, aging and self-healing abilities.

Education

  • M.D., University of Belgrade, 0 0 1984
  • Ph.D., University of Lund, 0 0 1991
  • Residency:

    • Gynecologic oncology, University of Lund, 1995
  • Fellowship:

    • Yale University School of Medicine, 2003
  • Certifications:

    • American Board of Obstetrics and Gynecology, 2004

Memberships and associations

  • Fellow, American Congress of Obstetricians and Gynecologists

Publications

  • "High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer." Gynecologic Oncology In: , Vol. 146, No. 1, 01.07.2017, p. 153-160.
  • "A recurrent endometrial stromal sarcoma harbors the novel fusion JAZF1-BCORL1." Gynecologic Oncology Reports  In: , Vol. 20, 01.05.2017, p. 51-53.
  • "Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer." Nature Genetics  In: , Vol. 49, No. 5, 01.05.2017, p. 680-691.
  • "Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma." Gynecologic Oncology In: , Vol. 145, No. 1, 01.04.2017, p. 78-87.
  • "No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival." Cancer Epidemiology Biomarkers and Prevention In: , Vol. 26, No. 3, 01.03.2017, p. 420-424.
  • "Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci." British Journal of Cancer  In: , Vol. 116, No. 4, 14.02.2017, p. 524-535.
  • "Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma." Gynecologic Oncology In: , Vol. 144, No. 2, 01.02.2017, p. 329-335.
  • "Predictors of pretreatment CA125 at ovarian cancer diagnosis : a pooled analysis in the Ovarian Cancer Association Consortium." Cancer Causes and Control In: , 03.01.2017, p. 1-10.
  • "Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus." Nature Communications  In: , Vol. 7, 12675, 07.09.2016.
  • "PALB2, CHEK2 and ATM rare variants and cancer risk : Data from COGS." Journal of Medical Genetics  In: , 02.09.2016.
  • "Genome-wide meta-analyses of breast, ovarian, and prostate cancer association studies identify multiple new susceptibility loci shared by at least two cancer types." Cancer Discovery  In: , Vol. 6, No. 9, 01.09.2016, p. 1052-1067.
  • "Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma." Annals of Oncology In: , Vol. 27, No. 7, mdw161, 01.07.2016, p. 1257-1266.
  • "No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer." Gynecologic Oncology  In: , Vol. 141, No. 2, 01.05.2016, p. 386-401.
  • "Nestin : A biomarker of aggressive uterine cancers." Gynecologic Oncology  In: , Vol. 140, No. 3, 01.03.2016, p. 503-511.
  • "Investigation of exomic variants associated with overall survival in ovarian cancer." Cancer Epidemiology Biomarkers and Prevention In: , Vol. 25, No. 3, 01.03.2016, p. 446-454.
  • "BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers." Journal of the National Cancer Institute In: , Vol. 108, No. 2, djv315, 01.02.2016.
  • "Gynecological oncologic emergencies."   Oncologic Emergency Medicine: Principles and Practice. Springer International Publishing, 2016. p. 351-358.
  • "Evidence of a genetic link between endometriosis and ovarian cancer." Fertility and Sterility In: , Vol. 105, No. 1, 2016, p. 35-43e10.
  • "Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer." Oncotarget  In: , Vol. 7, No. 6, 2016, p. 6353-6368.
  • "Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer." Oncotarget  In: , Vol. 7, No. 43, 2016, p. 69097-69110.
  • "Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility : Results from a large-scale collaboration." Oncotarget  In: , Vol. 7, No. 45, 2016, p. 72381-72394.
  • "Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes : Findings from the Ovarian Cancer Association Consortium." Clinical Cancer Research  In: , Vol. 21, No. 23, 01.12.2015, p. 5264-5276.
  • "Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk." Genetic Epidemiology In: , Vol. 39, No. 8, 01.12.2015, p. 689-697.
  • "Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer." Carcinogenesis  In: , Vol. 36, No. 11, 01.11.2015, p. 1341-1353.
  • "Identification of novel candidate biomarkers of epithelial ovarian cancer by profiling the secretomes of three-dimensional genetic models of ovarian carcinogenesis." International Journal of Cancer In: , Vol. 137, No. 8, 15.10.2015, p. 1806-1817.
  • "Network-based integration of GWAS and gene expression identifies a HOX-centric network associated with serous ovarian cancer risk." Cancer Epidemiology Biomarkers and Prevention  In: , Vol. 24, No. 10, 01.10.2015, p. 1574-1584.
  • "Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer." Nature Communications  In: , Vol. 6, 8234, 22.09.2015.
  • "New insights in the pathophysiology of ovarian cancer and implications for screening and prevention." American Journal of Obstetrics and Gynecology  In: , Vol. 213, No. 3, 01.09.2015, p. 262-267.
  • "Genome-wide significant risk associations for mucinous ovarian carcinoma." Nature Genetics  In: , Vol. 47, No. 8, 30.08.2015, p. 888-897.
  • "Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients." OncoImmunology  In: , Vol. 4, No. 8, 03.08.2015.

Additional information

Edit profile